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ABSTRACT
Adamantiades-Behçet disease (ABD) is a chronic multisystemic vasculitis that is able to affect any human organ or system
Recurrent oral ulcers are a very important clinical sign. ABD is a worldwide pathology, which prevalence varies according to 
the population and geographic location. Although ABD has been known for ages, its aetiology remains an enigma. Genetic, 
immunological and microbiological factors have been associated. A wide spectrum of clinical manifestations (oral, genital, 
cutaneous, ocular, neurological, vascular and gastrointestinal) and an unpredictable evolution with repeated periods of exa-
cerbation and remission are the most representative aspects of this pathology. The complex treatment of ABD requires a deep 
multidisciplinary cooperation; therefore, there is an extensive development of new therapeutic agents that have improved the 
prognosis of ABD.  In this review were analysed the main etiological, clinical and therapeutic aspects of the disease.  
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RESUMEN
La Enfermedad de Adamantiades-Behçet es una vasculitis multisistémica crónica, potencialmente capaz de afectar a cualquier 
órgano o sistema del cuerpo humano y en la que la aparición repetida de úlceras orales es una de sus principales expresiones 
clínicas. La EAB es una patología de carácter universal, con una prevalencia variable en función de la población estudiada y 
que muestra una curiosa distribución geográfica. A pesar de ser un proceso conocido desde la antigüedad, su etiopatogenia en 
la que probablemente se hayan implicados factores genéticos, microbiológicos e inmunológicos, continua siendo enigmática. 
Su amplio espectro  de manifestaciones clínicas orales, genitales, cutáneas, oculares, neurológicas, vasculares y gastrointes-
tinales y su impredecible evolución con periodos de exacerbación y de remisión son dos de los aspectos más representativos 
de esta patología. El complejo tratamiento de la EAB requiere una estrecha cooperación multidisciplinar dado su carácter 
multisistémico. Gracias a ello y al desarrollo de nuevos agentes terapéuticos su pronóstico ha mejorado sensiblemente con 
respecto a décadas pasadas. En esta revisión analizamos los principales aspectos etiopatogénicos, clínicos y terapéuticos de 
esta enfermedad.
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INTRODUCTION
Adamantiades-Behçet disease (ABD) is a multisystemic 
process, which aetiology remains unknown; however it 
might be produced by an immunological disorder which 
generates vasculitis (1, 2). Even though ABD might di-
ffer from each patient, recurrent oral ulcers are the most 
frequent manifestation of the disease, however vasculitis 
potentially involves almost every organ or system of the 
human body (1-3).
Although ABD was recognised primarily by Hippocrates 
on the V century BC, there are not any references regar-
ding the diseases until 1931, when the Greek ophthal-
mologist Benedict Adamantiades described it clinically 
(1, 4). Later, in 1937, the Turkish dermatologist Hulusi 
Behçet made a complete description of the disease and 
established the classical triad “oral, genital and ocular 
ulcers” (1, 4). Several subsequent investigations allowed 
relating other manifestations, as cutaneous, joint, digesti-
ve, vascular and neurological with the disease.
As a memory of Adamantiades’s contribution, some 
authors have considered (4) the term ABD more appro-
priated instead of “Behçet disease” only. Also, it is 
controversial whether the ABD should be considered “a 
disease” or “a syndrome”. Since it is a well described 
entity some people refer to it as “a disease”, however, 
lack of a knowing aetiology and a wide clinical range 
seem enough to call it “a syndrome” (1,2).
EPIDEMIOLOGY
ABD is a universal pathology, although it shows a sin-
gular geographic distribution. Its prevalence is high in 
Southeast Asia (2-20/100.000), Mediterranean countries 
and in the “silk path” countries (13-370/100.000). It is 
especially frequent in Japan (13-30/100.000), Turkey (80-
300/100.000) and South Korea, while its prevalence in 
low in the rest of the European countries and US (0,1-7,5 
casos/100.000) (5-8). Even though certain ethnic groups 
have shown a higher predisposition for the disease, it is 
debatable whether it is due to racial or geographic reasons 
(5-8). ABD afflicts females and males equally in almost 
all countries, apart from in Middle East countries as Iran, 
Turkey, Libya, Iraq, Jordania, Israel and Egypt, where 
studies have shown a higher prevalence among the male 
group (1.5-5:1) (5-8).
The beginning of the symptoms might appear at any age, 
however, most of the cases show them around the 3rd de-
cade of life and, usually the disease develops completely 
after 15 months of first appearance. There are hardly any 
cases of neonatal cases published and children are scar-
cely affected and show no clinical differences compared 
to adults (1-3). An early start of the disease in males is 
associated with an elevated clinical aggressiveness (9).
ETIOPATHOGENESIS  
The precise aetiology of ABD is still unknown and differs 
from the classical patterns of autoimmune diseases. The 
existence of family cases, the relation to a number of 
genes and its capricious geographic distribution suggest 
an association to genetic or environmental factors (1, 10). 
Nevertheless, since ABD does not follow Mendel’s laws, 
the number of familiar cases is very low (1-18%) and it 
has been impossible to find an exclusive gene alteration, 
the aetiology of ABD should not be considered solely 
genetic (1, 10). 
It has been demonstrated a narrow relation between ABD 
and the Major Histocompatibility Complex (MHC) gene 
HLA-B51, especially in Japan, the Middle East and the 
Mediterranean countries. This relationship has been ob-
served most commonly in men and in association with 
ocular symptoms (1-3). Other MHC genes interrelated 
with ABD are HLA-B27, linked to joint lesions, and 
HLA-B12, linked to mucocutaneous manifestations (1-3). 
Nowadays, many investigations are in progress with the 
intention of connecting alterations of HLA-DRw8, HLA-
B15 or MIC-A genes, as well as the adhesion molecule 
ICAM-1 with the vasculitis process (11-15). 
From the first descriptions of ABD, it has been speculated 
about the relation of the disease to infectious factors, mos-
tly based on the geographical distribution. Interestingly, 
even Behçet in the original publication, pointed a possible 
viral aetiology due to the appearance of genital and oral 
lesions (16). Several studies (1-3) have tried to prove the 
existence of a viral factor, in particular Herpes family, 
or a bacterial factor, specifically streptococci, without 
any luck. Different authors (1-3, 14, 15) have identified 
DNA of Herpes simplex type 1 from lymphocytes and 
monocytes, as well as a higher level of antibodies against 
Herpes simplex type 1 in patients with ABD. However, 
the proportion of patients with positive viral serology and 
positive viral DNA from biopsies was not statistically 
significant. The results of some studies in vitro (1-3, 14, 
15) have suggested the possibility that the hypersensibility 
to certain strains of Streptococcus sanguis might play a 
relevant role in the etiopathogenesis of the disease. In fact, 
the frequency of oral lesions might not be casual and be, 
in some way, related to oral streptococci. For the moment, 
lack of conclusive evidences forbids from estimating the 
relevance of infectious agents in ABD.  
Another piece of the puzzle represents the immunological 
alterations observed in patients with ABD. Up to 50% of 
patients show an increase of circulating immunocomplex 
during the exacerbation peaks of the disease (1-3, 10). 
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Some studies (10,14,15) have observed during active 
phases of the disease a decrease of CD4/CD8 lympho-
cyte ratio at the expense of an increase of the number of 
CD8+ lymphocytes, a decrease of natural killer (NK) 
cell activity or an increase of interleukin IL-2, IL-10 or 
tumour necrosis factor receptor-γ (TNFRγ) levels. Also, 
it has been observed an increase of γδ lymphocytes able 
to secrete lymphokines with cytotoxic activity (10, 14, 
15). Some of the substances produced by T lymphocytes 
might play an important role in aphthous stomatitis as 
fibroblast growth factor (FGF)-7, which stimulates and 
accelerates fibroblast proliferation, and tumour necrosis 
factor (TNF), which plays a key role in the pathogenesis 
of the oral lesions (10-12).
In the absence of a general consensus about the etiopa-
thogenesis, ABD should be considered a multifactorial 
disease, which cannot be classified isolated as a genetic, 
autoimmune or infectious disease.
CLINICAL FEATURES
Broad clinical spectrum and unpredictable evolution are 
the most representative characteristics of ABD (17). Oral, 
genital, cutaneous, ocular, neurological, vascular and 
gastrointestinal manifestations are some of the clinical 
aspects of the disease. 
1) Oral lesions: Oral ulcers are found in 95-100 % of 
the patients (1-3). Clinically, they are indistinguishable 
from recurrent aphthous stomatitis (RAS). Like RAS, 
oral ulcers are classified as: minors (< 1 cm.), majors 
(> 1 cm.) and herpetiform (1-3 mm) (1-17) (Figure 1). 
There are barely any difference between RAS and ABD. 
Nevertheless, ABD ulcers tend to appear in unusual places 
and in a higher number (17). Trauma has been observed 
as inductive factor in both processes, in addition to the 
protective role of tobacco, hypothetically based on the 
hyperkeratosis of the epithelia (17, 18). Oral lesions, in 
many cases, are the first sign of ABD and, in most of the 
patients, episodes of oral ulcers persist for 1 to 3 years 
before appearing the other signs of the disease (17, 18).
2) Genital lesions: Genital lesions are characterised by 
ulcers also, though they are less frequent than oral lesions 
(60-80%) (1-3). Ulcers may appear in any place of the 
genital area, most frequently on the male scrotum and 
minor and major females lips. Lesions are painful and 
may cause walk difficulties and even sometimes dysuria. 
Risk of infection is a common complication during the 
evolution of the lesions, which increases depending upon 
the size and depth of ulcers (1-3, 19).
3) Cutaneous lesions: Cutaneous manifestations are 
observed in 80% of patients with ABD.  The most com-
mon lesion represents erythema nudosum (40-50%) and 
pustules or acne-like lesions (60-70%) (20). Lesions 
erythema nudosum-like are more frequent on inferior 
limbs, and generally they do not ulcer. After healing they 
usually leave a hyperpigmented surface. Histologically, a 
focal vasculitis of small blood vessels is observed (20). 
Pustules or acne-like lesions may appear at any location 
and they are morphologically similar to adolescent acne. 
Histologically, besides vasculitis of small blood vessels, 
an inflammatory infiltrate compounded from neutrophils 
and necrosis is observed (20).
4) Ocular lesions: 20 to 50% of patients with ABD have 
ocular involvement (1-3). Habitually, they appear two or 
three years after the beginning of the disease. Manifesta-
tions may vary; from a mild conjunctivitis to a vasculitis 
or retina atrophy, glaucoma, cataracts or retina loosening 
(17, 21) (Figure 2). The severity of the ocular manifesta-
tions is variable and generally bilateral, total or partial lost 
of the sight is observed in 25% of the patients (21). 
5) Joint lesions: Up to 45-50% of patients with ABD 
may show non deforming arthritis, in one or more joints, 
which last several days or weeks, mainly affecting limb 
joints (1-3, 17). 
6) Neurological lesions: 5 to 20% of the patients might 
develop brain or spinal medulla damage or meningitis 
(22). Clinically, it is manifested by emotional and sen-
sorial alterations, paralysis, paresis, and even severe 
psychiatric disorders. Cerebrospinal fluid may appear 
normal or show an increase of neutrophils, lymphocytes 
or proteins (17, 22).
7) Vascular lesions: Basically, any lesion associated to 
ABD is produced directly or indirectly by vasculitis. 
Vasculitis may affect any kind of blood vessels; arteries, 
veins, deep or superficial; however, small calibre vessels 
are the most common (23). Tendency for thrombosis is 
very common, either superficial or deep, particularly in 
the inferior limbs. Fortunately, complications as lung 
emboli are rare. For that reason, it is very controversial 
the use of preventive anticoagulants in patients with 
ABD (17, 23). The risk of arterial aneurysms and arterial 
obstruction is higher in ABD patients than healthy indi-
viduals. Involvement of major arteries may cause fatal 
consequences (23).
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Fig. 1. Oral ulcers Fig. 2.  Uveitis
8) Gastrointestinal lesions: Prevalence of gastrointestinal 
lesions varies among the population studied. There are 
particularly frequent amongst Japanese (1-3, 17). Primary 
manifestations are ulcers, which can appear from the 
oesophagus to the rectum. Symptoms differ according 
to location and severity of the lesion (abdominal pain, 
dysphagia, diarrhoea, etc). Although these lesions are 
infrequent, complications may be severe (17).
9) Other lesions: There are numerous alterations that 
have been associated to ABD, however, they seem less 
frequent than the manifestations described above. The 
most important are the cardiac complications (pericar-
ditis, coronary thrombosis, valve prolapse), follow by 
renal (proteinuria, haematuria or glomerulonephritis), 
pulmonary and pleurae complications (17-23). 
DIAGNOSIS
Diagnosis of ABD remains difficult, due to the absence 
of a conclusive diagnostic test that confirms the clinical 
diagnosis (1-3). In ancient times “pathergy test” had a 
great relevance. This test measures the reaction after 24 
or 48 hours after an intradermal injection in the forearm 
(It is considered positive whether an erythematous nodule 
or pustule larger than 2 mm is formed). Unfortunately the 
test might result negative in up to 50% of cases (24). 
In order to unify inclusion criteria, several groups have 
established different classifications. The classification 
produced in 1990 by the International Study Group for 
Behçet’s Disease is the most accepted among the interna-
tional scientific community (25). In this classification is 
indispensable for the diagnosis 3 episodes of oral ulcers 
within a 12 month period. Also, patient must have suffe-
red at least 2 of the 4 following manifestations: repeated 
genital ulcers, ocular lesions, cutaneous lesions or posi-
tive pathergy test (25) (Table I). The real applicability 
of these criteria is for research more than for the clinical 
practice, as many patients, without filling all the inclusion 
Recurrent oral ulcers Major, minor or herpetiform. 3 or more episodes in a 
12 month period
                      + 2 manifestations of: 
Recurrent genital ulcers Repeated apthous ulceration  
Ocular lesions Anterior / posterior uveitis 
Retinal vasculitis
Cutaneous lesions erythema nudosum  
Pseudofolliculitis popular-pustules or acne-like lesions 
Positive “pathergy test” > 2mm at 24-48 hours 
Table 1. Diagnostic criteria for ABD (28).
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standards, have clinical features completely consistent to 
the diagnosis of EAB (24).
As any other disease, or even more due to the absence 
of diagnostic tests, it is essential to complete a meticu-
lous clinical history in order to establish the appropriate 
differential diagnoses. Depending on the type of clinical 
manifestation differential diagnosis should be established 
with RAS, Neumann aphtous stomatitis, Reiter syndrome, 
sarcoidosis, multiple sclerosis, Steven-Johnson syndrome, 
PFAPA syndrome, MAGIC syndrome, Crohn disease or 
celiac disease.
TREATMENT
Owing to the multiple organ and tissue involvement of 
ABD, therapy must be performed for a group of different 
health professionals. The correct treatment requires a na-
rrow collaboration among different practitioners in order 
to coordinate an individual protocol for each patient. The 
therapy always combines a general and an organ-specific 
approach (26). General therapy controls the active periods 
of the disease and consists of different anti-inflammatory 
drugs, steroids or immunotherapy (26). Among the new 
drugs, use of alpha interferon 2A and B are showing good 
results. They seem to reduce and prevent symptoms; 
however, hardly any studies have been done with ABD 
patients (27).
Regarding to oral lesion treatment, it is basically the same 
as the one indicated for RAS. Topical treatments are indi-
cated for mild lesions and systemic treatments for severe 
lesions (28, 29). Among topical therapies, use of steroids 
is the most popular choice. Triamcinolone (0,05-0,5%), 
fluocinolone (0,05-0,1 %), clobetasol (0,05-0,1%) and 
betametasone (0,1%) reduce the symptoms and duration 
of the ulcers, though they do not prevent recurrences (26-
29). The effectiveness of topical drugs, as anaesthetics, 
antiseptics, and analgesics is limited, thus they should be 
used as a complementary therapy only (28, 29).
When oral lesions are severe systemic therapies are in-
dicated. Employ of immunodrugs as thalidomide, tacro-
limus, azathioprine, azelastine or metotrexate decreases 
the number of lesions, length and pain, and increases the 
latency period. However, these drugs produce important 
secondary effects as teratological anomalies, severe di-
gestive disturbances, haematological problems, etc. For 
those reasons, indication and use of those drugs must be 
continuously supervised and women potentially fertile 
must follow strict programs to prevent conception. Dose 
is individualised and should be rigorously followed (26-
29). Systemic steroids, as prednisone at different dosage, 
produce rapid heal and longer latency periods, however, 
its administration must be indicated under strict mea-
sures to guarantee minimal side effects (28, 29). Other 
medicaments like pentoxifiline, an inmunomodulator, or 
colchicine, an antifungal drug, reduce and prevent new le-
sions even when the therapy has ended. Their mechanism 
of action remains unknown (26-29). As the other drugs 
mentioned above, use of pentoxifiline and colchicine must 
be indicated under strict surveillance.
 
PROGNOSIS
ABD is a chronic disease and show surprising periods of 
remission and activity. Generally, frequency and intensity 
of the disease decrease with time, though patient evolution 
is still unpredictable. Depending on the organs and tissues 
involved, mobility may change. Up to 20% of patients 
may have a severe evolution and develop several compli-
cations as: thrombosis, intestinal perforation, myocardial 
infarct, aneurisms and others, which could cause death of 
patient. Fortunately, those cases are rare and preventive 
therapies reduce the mortality to levels similar to the 
general population rate (30). Mobility, however, is still 
very high accompanied with complications as blindness 
or severe arthritis.
REFERENCES
1. Kontogiannis V, Powell RJ. Behçet´s disease. Postgrad Med J 2000;76: 
629-37.
2. Lee LA. Behcet disease. Semin Cutan Med Surg 2001;20:53-7.
3. Barnes CG, Yazici H. Behcet´s Syndrome. Rheumatology 1999;38:1171-6.
4. Dimakakos PB, Tsiligiris B, Kotsis T. The physician B. Adamantiades 
and his contribution to the disease Adamantiades-Behcet. Int Angiol 1999; 
18:176-81.
5. Zouboulis CC. Epidemiology of Adamantiades-Behçet´s disease. Ann Med 
Int 1999;150:488-98.
6. Jaber L, Milo G, Halpern GJ, Krause I, Weinberger A. Prevalence of Behçet´s 
disease in an arab community in Israel. Ann Rheum Dis 2002;61:365-6.
7. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet´s disease, 
the silk road and HLA-B51: historical and geographical perspectives. Tissue 
Antigens 1999;54:213-20.
8. Zouboulis C, Kotter I, Djawari D, Kirch W, Kohl P, Ochsendorf FR et al. 
Epidemiological features of Adamantiades- Behçet´s disease in Germany and 
in Europe. Yonsei Med J 1997;38:411-22.
9. Yacizi H, Yurdakul S, Tüzün Y. Influence of age and onset and patient´s 
sex on the prevalence and severity of manifestations of Behçet´s disease. Ann 
Rheum Dis 1984;43:783-9.
10. Onder M, Gurer MA. The multiple faces of Behçet´s disease and its aetio-
logical factors. J Eur Acad Dermatol Venereol 2000;15:126-36.
11. Lehner T, Welsh KI, Batchelor JR. The relationship of HLA-B and DR 
phenotypes to Behçet´s syndrome, recurrent oral ulceration and the class of 
immune complexes. Immunology 1982;47:581-7.
12.  Kim EH, Mok JW, Bang D, Lee ES, Lee S, Park K. Intercellular adhesion 
molecule-1 polymorphisms in Korea patients with Behçet´s disease. J Korean 
Med Sci 2003;18:415-8.
13. Sun A, Hsieh RP, Chu CT, Wang JT, Liu BY, Chiang CP. Some specific 
human leukocyte antigen (HLA)-DR/DQ haplotypes are more important than 
individual HLA-DR and –DQ phenotypes for the development of mucocuta-
neous type of Behçet´s disease and for disease shift from recurrent aphthous 
stomatitis to mucocutaneous type of Behçet´s disease. J Oral Pathol Med 
2001;30:402-7.
14. Meador R, Ehrlich G, Von Feldt JM. Behçet´s disease: immunopathologic 
and therapeutic aspects. Curr Rheumatol Rep 2002;4:47-54.
15. Emmi L, Brugnolo F, Marchione T. Pathogenesis and therapy of Behçet´s 
disease. Ann Ital Med Int 1997;12:20-5.
Oral Medicina and Pathology                                                                                                                       Adamantiades-Behçet disease              Med Oral Patol Oral Cir Bucal 2006;11:E6-11.                                                                                       Adamantiades-Behçet disease
E11
16.Behçet H. Uber rezidivierende, aphtose, durch ein virus verursachte. 
Geschwure am Mund, am Auge und an den Genitalen. Dermatol Wochenchir 
1937;36:1152-7.
17.Bang D. Clinical spectrum of Behçet´s disease. J Dermatol 2001;28: 
610-3.
18. Rizvi SW, McGrath H Jr. The therapeutic effect of cigarette smoking on 
oral/genital aphtosis and other manifestations of Behçet´s disease. Clin Exp 
Rheumatol 2001;19:77-8.
19. Cappele O, Nicolas J, Bottet P, Bensadoum H. Urological manifestations 
of Behçet´s disease. Prog Urol 2003;77:329-31.
20. Lee E, Bang D, Lee S. Dermatologic manifestations of Behçet´s disease. 
Yonsei Med J 1997;38:380-9.
21. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgacio-
glu M. Uveitis in Behçet disease: An analysis of 880 patients. Am J Ophtalmol 
2004;138:373-80.
22. Silva A, Altintas A, Saip S. Behcet´s syndrome and the nervous system. 
Curr Opin Neurol 2004;17:347-57.
23. Koc Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S et al. Vascular 
involvement in Behçet´s disease. J Rheumatol 1992;19:402-10.
24. Kyu H, Cheon KS. The clinical significance of a pathergy reaction in 
patients with Behçet´s disease. J Korean Med Sci 2002;17:371-4.
25. International Study Group for Behçet´s Disease. Criteria for diagnosis of 
Behçet´s disease. Lancet 1990;335:1078-80.
26. Whallet AJ, Thurairajan G, Hamburger J, Palmer RG, Murray PI. Behçet´s 
syndrome: a multidisciplinary approach to clinical care. Q J Med 1999;92: 
727-40.
27. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha 
in Behcet disease: review of the literature. Semin Arthritis Rheum 2004; 
33:320-35.
28. Sakane T, Takeno M. Current therapy in Behçet´s disease. Skin Therapy 
Lett 2000;5:3-5.
29. Barrons RW. Treatment strategies for recurrent oral aphtous ulcers. Am J 
Health Syst Pharm 2001;58:41-53.
30. Yacizi H, Basaran G, Hamuryudam V, Hizli N, Yurdakul S, Mat C et al. The 
ten-year mortality in Behçet´s syndrome. Br J Rheumatol 1996;35:139-41.
 
 
 
